We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$22.8B
AUM Growth
-$510M
Cap. Flow
-$2.26B
Cap. Flow %
-9.9%
Top 10 Hldgs %
40.08%
Holding
187
New
21
Increased
43
Reduced
39
Closed
22

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$207M
2
ANSS
Ansys
ANSS
+$201M
3
WWD icon
Woodward
WWD
+$192M
4
SWN
Southwestern Energy Company
SWN
+$168M
5
SQSP
Squarespace, Inc.
SQSP
+$130M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$294M
2
NDAQ icon
Nasdaq
NDAQ
+$256M
3
CRM icon
Salesforce
CRM
+$231M
4
AZN icon
AstraZeneca
AZN
+$188M
5
ARMK icon
Aramark
ARMK
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 31.84%
2 Technology 13.48%
3 Financials 9.84%
4 Communication Services 6.79%
5 Industrials 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRKR icon
101
Bruker
BRKR
$9.07B
$2.21M 0.01%
+32,000
New +$2.07M
ELEV
102
DELISTED
Elevation Oncology
ELEV
$2.12M 0.01%
3,527,482
-70,936
-2% -$105K
SMC
103
Summit Midstream
SMC
$470M
$2.04M 0.01%
58,214
– –
GATE
104
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.66M 0.01%
150,000
– –
GRND.WS
105
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$1.64M 0.01%
540,000
– –
MDGL icon
106
Madrigal Pharmaceuticals
MDGL
$11.9B
$704K ﹤0.01%
3,319
– –
TVRD
107
Tvardi Therapeutics
TVRD
$24.8M
$479K ﹤0.01%
43,229
– –
ROIV icon
108
Roivant Sciences
ROIV
$26.2B
$427K ﹤0.01%
37,000
-636,000
-95% -$7.24M
HCA icon
109
HCA Healthcare
HCA
$92.9B
$406K ﹤0.01%
1,000
– –
FBRX icon
110
Forte Biosciences
FBRX
$1.63B
$406K ﹤0.01%
72,413
-5
-0% -$51
BPMC
111
DELISTED
Blueprint Medicines
BPMC
$370K ﹤0.01%
4,000
– –
KRYS icon
112
Krystal Biotech
KRYS
$10.3B
$364K ﹤0.01%
2,000
– –
AXSM icon
113
Axsome Therapeutics
AXSM
$10.9B
$359K ﹤0.01%
4,000
– –
UTHR icon
114
United Therapeutics
UTHR
$22B
$358K ﹤0.01%
1,000
-142,000
-99% -$48M
IMVT icon
115
Immunovant
IMVT
$9.16B
$342K ﹤0.01%
12,000
– –
GKOS icon
116
Glaukos
GKOS
$10.9B
$339K ﹤0.01%
2,600
– –
ACLX
117
DELISTED
Arcellx
ACLX
$334K ﹤0.01%
4,000
– –
BTSG icon
118
BrightSpring Health Services
BTSG
$11.6B
$323K ﹤0.01%
22,000
– –
SAGE
119
DELISTED
Sage Therapeutics
SAGE
$309K ﹤0.01%
42,800
– –
MMSI icon
120
Merit Medical Systems
MMSI
$5.42B
$296K ﹤0.01%
3,000
– –
EHC icon
121
Encompass Health
EHC
$11.9B
$290K ﹤0.01%
3,000
– –
SBRA icon
122
Sabra Healthcare REIT
SBRA
$5.21B
$261K ﹤0.01%
14,000
– –
GMED icon
123
Globus Medical
GMED
$11.7B
$258K ﹤0.01%
3,600
– –
ICUI icon
124
ICU Medical
ICUI
$4.57B
$255K ﹤0.01%
+1,400
New +$207K
GRFS
125
Grifois
GRFS
$5.44B
$249K ﹤0.01%
28,000
– –
3 4
5
6 7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2024 Portfolio in Review

As of Q3 2024, Thomas Steyer held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Woodward worth $198M.

  • Thomas Steyer's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
  • Thomas Steyer added most to Walt Disney in Q3 2024, an estimated $207M increase.
  • Thomas Steyer's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
  • Thomas Steyer fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
  • Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
  • Thomas Steyer opened 21 new positions and closed 22 in Q3 2024.
  • Thomas Steyer's portfolio value fell 2.2% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.